Molecular Detection of oprD resistant Gene among Carbapenem Resistant Pseudomonas aeruginosa Clinical Isolates, Khartoum State-Sudan
Abstract
Background
Carbapenems are the most important therapeutic options that effect against serious infections caused by multidrug resistant Pseudomonas aeruginosa isolates; however recently carbapenems resistant isolates of P.aeruginosa are increasing worldwide. It is often due to the impermeability that arises via the loss of the OprD porin, the overproduction of an active efflux pump system, and the production of carbapenem-hydrolyzing ß-lactamase
Objectives: This study aimed to detect oprD gene among carbapenem resistance P. aeruginosa clinical isolates using conventional PCR technique during the period from September 2018 to August 2021.
Methods: Hundred carbapenem resistance Pseudomonas aeruginosa clinical isolates were collected from different specimens from Soba Hospital, Fedail Hospital and Military Hospital for this study in Khartoum State, Sudan. All isolates were re-identified using conventional bacteriological techniques and their susceptibility to carbapenem was tested using Kirby-Bauer method for confirmation. All isolates were investigated for the presence of oprD gene using polymerase chain reaction (PCR).
Results: Of the 100 clinical isolates, the oprD gene expressed in 10 (10%) isolates and it was not detected among the remainder (90%), the higher percentage was found among the isolates from wound swabs 5 (50%), whereas it was not detected among the isolates from high vaginal swabs, nibble discharge and sputum samples (P value = 0.02).
Conclusions: The oprD gene was not detected among the vast majority of isolates such findings can supports the idea that the basic mechanism of carbapenem resistance could be via the loss of oprD porine gene.
References
2. Williams BJ, Dehnbostel J, and Blackwell TS, “Pseudomonas aeruginosa: host defense in lung diseases,” Respirology, vol. 15, no. 7, pp. 1037–1056, 2010.
3. Gellatly SL and Hancock REW, “Pseudomonas aeruginosa: new insights into pathogenesis and host defenses,” Pathogens and Disease, vol. 67, no. 3, pp. 159–173, 2013.
4. Chastre J and Fagon JY, “Ventilator-associated pneumonia,” American Journal of Respiratory and Critical Care Medicine, vol. 165, no. 7, pp. 867–903, 2002.
5. Sonbol, F.I., Khalil, M.A.E.F., Mohamed, A.B. and Ali, S.S., (2015). Correlation between antibiotic resistance and virulence of Pseudomonas aeruginosa clinical isolates. Turkish Journal of Medical Sciences, 45(3), pp.568-577.
6. Kohler T, Curty LK, Barja F, van Delden C, Pechere J. Swarming of pseudomonas aeruginosa is dependent on cell-to-cell signaling and requires flagella and pili. J Bacteriol. 2000 November 1;182(21):5990-6.
7. Li H, Estabrook M, Jacoby GA, Nichols WW,Testa R, Bush K. In vitro s usceptibility of characterized beta-lactamase-producing strains tested with avibactam combinations. Antimicrob Agents Chemother, 2015; 59(3):1789–1793
8. Kirikae T, Mizuguchi Y, Arakawa Y. (2008) Investigation ofisolation rates of Pseudomonas aeruginosa with and without multidrug resistance in medical facilities and clinical laboratories in Japan.2008; J Antimicrob Chemother 61: 612–5
9. Borgianni L, Prandi S, Salden L, Santella G, Hanson ND, Rossolini GM, et al. Genetic context and biochemical characterization of IMP-18 metallo-beta lactamase identified in a Pseudomonas aeruginosa isolate from the United States. Antimicrob. Agents Chemother. 2011; 55:140–145.
10. Büscher KH, Cullmann W, Dick W, Opferkuch W. Imipenem resistance in Pseudomonas aeruginosa resulting from diminished expression of an outer membrane protein. Antimicrob. Agents Chemother. 1987; 31:703–708.
11. Terzi HA, Kulah C, Atasoy AR, Ciftci IH. Investigation of OprD porin protein levels in carbapenem-resistant Pseudomonas aeruginosa isolates. Jundishapur journal of microbiology. 2015; 8(12).
12. Dahab RA, Alamin AM, Altayb HN. Phenotypic and genotypic detection of carbapenemase enzymes producing gram negative bacilli isolated from patients in Khartoum state. 2017; F1000 Research, 6: 16-56.
13. Sanbongi Y, Shimizu A, Suzuki T, Nagaso H, Ida T, Maebashi K, Gotoh N. Classification of OprD sequence and correlation with antimicrobial activity of carbapenem agents in Pseudomonas aeruginosa clinical isolates collected in Japan. Microbiology and immunology. 2009;53(7):361-7
14. Strateva T, Yordanov D. Pseudomonas aeruginosa - a phenomenon of bacterial resistance. J Med Microbiol. 2009;58(Pt 9):1133–48.
15. Sakyo S, Tomita H, Tanimoto K, Fujimoto S, Ike Y. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem. J Antibiot (Tokyo). 2006;59(4):220–8.
16. El Amin N, Giske CG, Jalal S, Keijser B, Kronvall G, Wretlind B. Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates. APMIS. 2005;113(3):187–96.
17. Fournier D, Richardot C, Muller E, Robert-Nicoud M, Llanes C, Plesiat P, et al. Complexity of resistance mechanisms to imipenem in intensive care unit strains of Pseudomonas aeruginosa. J Antimicrob Chemother. 2013;68(8):1772–80
18. Vatcheva-Dobrevska R, Mulet X, Ivanov I, Zamorano L, Dobreva E, Velinov T, et al. Molecular epidemiology and multidrug resistance mechanisms of Pseudomonas aeruginosa isolates from Bulgarian hospitals. Microb Drug Resist. 2013;19(5):355–61
19. Hong DJ, Bae IK, Jang IH, Jeong AH, Kang H, Lee K. Epidemiology and characteristics of metallo-β-lactamase-producing Pseudomonas aeruginosa. Infect Chemother. 2015;47(2):81–97
20. López-García A, del Carmen Rocha-Gracia R, Bello-López E, Juárez-Zelocualtecalt C, Sáenz Y, Castañeda-Lucio M, et al. Characterization of antimicrobial resistance mechanisms in carbapenem-resistant Pseudomonas aeruginosa carrying IMP variants recovered from a Mexican Hospital. Infection and drug resistance, 2018; 11, p.1523.
